|
US5409690A
|
|
Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol
|
|
US5362737A
|
|
Methods of treating aphthous ulcers and other mucocutaneous disorders with amlexanox
|
|
US5166149A
|
|
Methotrexate compositions and methods of treatment using same
|
|
WO9205200A1
|
|
Xenobiotic-antibody conjugates
|
|
AU6734590A
|
|
Xenobiotic-antibody conjugates
|
|
AU3056889A
|
|
Selective inhibition of gene expression by photoactivatable oligonucleotides
|
|
US4954659A
|
|
1,4-bis (dihydroxyphenyl) butane and analogs
|
|
EP0324802A1
|
|
Method for the treatment of body tissues and the administration of drugs thereto
|
|
DK338887D0
|
|
Racemic nordihydroguaaric acid and intermediate products
|
|
US5008294A
|
|
Methods of treating tumors with compositions of catecholic butanes
|
|
AU7484887A
|
|
Method for inhibiting aging
|
|
AU6737987A
|
|
Pharmacologically active compositions of catecholic butanes with zinc
|
|
WO8803806A1
|
|
Pharmacologically active compositions of catecholic butanes with zinc
|
|
AU6737587A
|
|
Lipoxygenase inhibitors
|
|
AU6779487A
|
|
Pharmacologically active compounds and mixtures thereof, organic compositions and metal salts
|
|
AU6723387A
|
|
Pharmaceutical vehicles for reducing transdermal flux
|
|
WO8803799A1
|
|
Pharmaceutical vehicles for reducing transdermal flux
|
|
EP0290442A1
|
|
Pharmacologically active compounds and mixtures thereof, organic compositions and metal salts.
|
|
EP0289506A1
|
|
Lipoxygenase inhibitors
|
|
US4880637A
|
|
Compositions of catecholic butanes with zinc
|
